A randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma.
To assess the effectiveness of IV and nebulised magnesium sulphate in the treatment of acute severe asthma.
Multi centre randomised controlled trial of intravenous (IV) or nebulised magnesium sulphate versus placebo for acute severe asthma
Professor Steve Goodacre
Professor Alasdair Gray
S Goodacre, J Cohen, M Bradburn, A Gray, J Benger, T Coats on behalf of the 3Mg Research Team. The 3Mg Trial: Randomised controlled trial of intravenous or nebulised magnesium sulphate or standard therapy for severe acute asthma. The Lancet Respiratory Medicine. (2013); 1:293 – 300.
Goodacre S, Cohen J, Bradburn M, Stevens J, Gray A, Benger J, et al. The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. . Health Technology Assessment. (2014);18(22).
Evaluating the role of early CT Coronary Angiography on patients with suspected or confirmed Acute Coronary Syndrome.
Evaluating the role of early CT Coronary Angiography
ETNA: Edinburgh Transient and Neurological attack: A Cohort Study
Patients frequently present with minor neurological symptoms where a diagnosis of transient ischaemic attack (TIA) or minor stroke is difficult to make positively or to exclude reasonably. For these patients, clinicians are uncertain whether they should: (a) reassure most patients that their symptoms are benign; (b) treat most patients with antiplatelet or other vascular prevention; or (c) stratify stroke risk further using clinical features or brain imaging.
This is important because clinical diagnosis is difficult. Mis-diagnosis is not infrequent and leads to harm from preventable recurrent stroke and costs to health systems from extra care and legal liabilities.
All ETNA participants will receive an MRI scan and the study aims to establish the feasibility and methods for a larger study of diagnostic utility of MR brain imaging and estimate the effects of MRI on clinician decision making.
This study has been recruiting in the Emergency Dept, inpatient wards and TIA clinics since August 2018. We aim to recruit 270 participants and have almost reached our target!
EHA - Epidemiological analysis for the Hereditary Angioedema Disease is an international, multicentre, epidemiological study that aims to explore the feasibility of a new Dried Blood Spot (DBS) filtercard-based screening algorithm and thereby the prevalence of the Hereditary Angioedema.
EHA - Epidemiological analysis for the Hereditary Angioedema Disease